Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00NXT
|
|||
| Former ID |
DNCL003798
|
|||
| Drug Name |
Xmab 5871
|
|||
| Synonyms |
XmAb 5871 (TN)
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 2 | [1] | |
| IgG4 related disease [ICD-11: 4A43.0; ICD-10: M35, M35.8] | Phase 2 | [2] | ||
| Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [2] | ||
| Rheumatoid arthritis [ICD-11: FA20] | Phase 1/2 | [3] | ||
| Company |
Amgen; Xencor
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035125) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02867098) XmAb5871 Bioavailability Study | |||
| REF 4 | Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64. | |||
| REF 5 | Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. | |||
| REF 6 | CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.